Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Endo agreed to buy Par for $8.05B 'amid hunt for deals,' positioning the move within a broader specialty-pharma M&A wave driven by tax-inversion structures and…
Roughly one year post-close, Endo was talking about pricing pressure and 'generics market turmoil' on Par's portfolio, an early signal that the $8B thesis was…
Post-Mallinckrodt merger, the combined entity rebranded as Keenova and spun the legacy Par generics business out as 'Par Health' — a retrospective signal that…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Endo agreed to acquire Par Pharmaceutical from TPG-led investors for approximately $8.05B ($1.6B stock + $4.1B cash + $2.4B assumed debt), positioning Endo's Qualitest unit as a top-five US generics player. Closed September 28, 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo International plc / Par Pharmaceutical Holdings, Inc. (this deal) | 2015 | $8.1B | 15 |
| Endo International plc / Auxilium Pharmaceuticals, Inc. | 2014 | $2.6B | 47 |
| Endo International plc / DAVA Pharmaceuticals, Inc. | 2014 | $600M | 25 |
| Endo International plc / Grupo Farmaceutico Somar SAPI de CV | 2014 | $270M | 18 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2015 deals · Endo International plc deals · Other deals